Patients

MATERIALS AND METHODS
The first patient was a 45-yr-old white man who was diagnosed in
1977.
In subsequent years he was treated with melphalan-predni- 
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Complement Levels
Serum levels of C3 and C4 were normal throughout the observation periods during and after therapy in both patients. C3a and C5a were never elevated. Thus, there was no evidence of activation of the classical or
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